IP Library › Patent Application 19351393
Patent Application
App. No. 19/351,393

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/351,393
Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Claims (14)

1 - 4 . (canceled)

5 . A pharmaceutical composition comprising a compound of Formula IB which is

or a pharmaceutically acceptable salt thereof.

6 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula IB is present in an amount of about 1 μg to about 500 μg.

7 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula IB is present in an amount of about 5 μg to about 500 μg.

8 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula TB is present in an amount of about 10 μg to about 250 μg.

9 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula IB is present in an amount of about 10 μg to about 100 μg.

10 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula TB is present in an amount of about 10 μg to about 50 μg.

11 . The pharmaceutical composition according to claim 5 , wherein the compound of Formula IB is present in an amount of about 12.5 μg to about 50 μg.

12 . The pharmaceutical composition according to claim 5 , further comprising a gamma-secretase inhibitor selected from the group consisting of nirogacestat or a pharmaceutically acceptable salt thereof, crenigacestat or a pharmaceutically acceptable salt thereof, AL101 or a pharmaceutically acceptable salt thereof, AL102 or a pharmaceutically acceptable salt thereof, semagacestat or a pharmaceutically acceptable salt thereof, avagacestat or a pharmaceutically acceptable salt thereof, and ianabecestat or a pharmaceutically acceptable salt thereof.

13 . The pharmaceutical composition according to claim 5 , further comprising nirogacestat, or a pharmaceutically acceptable salt thereof.

14 . The pharmaceutical composition according to claim 5 , further comprising a pharmaceutically acceptable carrier.

15 . The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is for oral administration.

16 . The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is a tablet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: PATTERSON, KRISTIN; HATCHER, MARK
To: SPRINGWORKS THERAPEUTICS, INC.
Reel/Frame 072487/0538 →